European heart journal open最新文献

{"title":"Sex differences in out-of-hospital cardiac arrest.","authors":"Nertila Zylyftari, Mads Wissenberg, Filip Gnesin, Amalie Lykkemark Møller, Elisabeth Helen Anna Mills, Sidsel G Møller, Britta Jensen, Kristian Bundgaard Ringgren, Hanno L Tan, Fredrik Folke, Gunnar Gislason, Christian Torp- Pedersen, Christina Ji-Young Lee","doi":"10.1093/ehjopen/oeaf047","DOIUrl":"10.1093/ehjopen/oeaf047","url":null,"abstract":"<p><strong>Aims: </strong>The impact of resuscitation care initiatives on sex-differences in out-of-hospital cardiac arrest (OHCA) survival remains unclear. We aim to examine sex-differences in characteristics and survival.</p><p><strong>Methods and results: </strong>This Danish register-based study (2001-2020) included adult patients with a presumed cardiac cause of arrest. Temporal trends in survival were stratified by sex and subgroups: (i) bystander-witnessed status; (ii) bystander cardiopulmonary resuscitation (CPR); (iii) initial shockable heart rhythm; and age groups of <50, 50-75, and >75 years. To examine the association between sex and survival, we conducted adjusted logistic regression analyses. Among 50 066 OHCAs, women represented 34%. Women were older, had more chronic obstructive pulmonary disease, and lower prevalence of cardiovascular and cardiometabolic conditions than men. Women also had more OHCA at home (83.4 vs. 74.1%), fewer witnessed arrests (48.1 vs. 52.9%), half the probability of initial shockable heart rhythm (13.6 vs. 27.6%), and similar rates of receiving bystander-CPR. Survival rates improved over time for both sexes, but men had higher 30-day survival than women, even in subgroup and adjusted analyses [odds ratios (OR): 1.29; 95% confidence intervals (CI): 1.15-1.45, <i>P</i> < 0.001]. Sex-differences in survival were larger among those aged 50-75 years (in absolute and relative rates) and bystander witnessed arrests, while differences were smaller in those with initial shockable heart rhythms.</p><p><strong>Conclusion: </strong>Despite increases in 30-day survival for both sexes, women consistently had lower survival rates than men. Sex-differences were larger among those aged 50-75 years or with bystander witnessed arrests, but smaller in the subset of patients with an initial shockable heart rhythm.</p>","PeriodicalId":93995,"journal":{"name":"European heart journal open","volume":"5 3","pages":"oeaf047"},"PeriodicalIF":0.0,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12089750/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144112139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardioprotective drugs and heart failure/cardiomyopathy incidence in chemotherapy-treated cancer survivors of breast cancer and non-Hodgkin lymphoma: a retrospective cohort study in England.","authors":"Pooja Hindocha, Alexander R Lyon, Krishnan Bhaskaran, Helen Strongman","doi":"10.1093/ehjopen/oeaf039","DOIUrl":"10.1093/ehjopen/oeaf039","url":null,"abstract":"<p><strong>Aims: </strong>Evidence for the use of beta-blockers, angiotensin II receptor blockers (ARB), or angiotensin-converting enzyme inhibitors (ACEi) to mitigate chemotherapy-induced cardiotoxicity is inconclusive. The objectives are to investigate associations between prescription of ARBs, ACEis, and/or beta-blockers in the year following cancer diagnosis and subsequent risk of heart failure/cardiomyopathy (HF/CM) in chemotherapy-treated breast cancer and non-Hodgkin lymphoma (NHL) survivors.</p><p><strong>Methods and results: </strong>This cohort study used linked English electronic healthcare records from 9875 adult (≥18 years) breast cancer and NHL survivors who received chemotherapy. Cox regression was used to estimate the association between primary care-prescribed beta-blocker, ARB, and ACEi use in the year following cancer diagnosis, and subsequent HF/CM incidence, adjusting for potential confounders. Likelihood ratio tests were used to assess effect modification. The mean follow-up duration was 4.9 years (maximum 21.4). After adjusting for age, the risk of HF/CM was higher in the exposed group [hazard ratio (HR): 1.69, 95% confidence interval (CI): 1.34-2.14], but further adjustment for gender, comorbidities, and other medications reduced the association to close to null (HR: 1.07, 95% CI: 0.68-1.69). There was no evidence that the association differed by cancer site, age, radiotherapy, prior cardiovascular disease, or years since cancer diagnosis.</p><p><strong>Conclusion: </strong>We found no evidence that general practitioner prescribed beta-blocker, ARB, or ACEi use was associated with a reduced incidence of HF/CM in this population of chemotherapy-treated breast cancer and NHL survivors. This might be because the drug dosage and timing were not optimized to prevent chemotherapy-related cardiac damage; residual confounding by indication may also have obscured any treatment benefit.</p>","PeriodicalId":93995,"journal":{"name":"European heart journal open","volume":"5 3","pages":"oeaf039"},"PeriodicalIF":0.0,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12066945/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144033084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiovascular disease in breast cancer patients: a nationwide real-world evidence study 2013-20.","authors":"Ingrid Engebretsen, Francisco Oteiza, Elisabeth Floberghagen Birkelund, Signe Marie Brandal, Christoffer Bugge, Sigrun Halvorsen","doi":"10.1093/ehjopen/oeaf043","DOIUrl":"https://doi.org/10.1093/ehjopen/oeaf043","url":null,"abstract":"<p><strong>Aims: </strong>Various measures have been implemented in clinical practice to reduce the risk of cardiovascular complications during breast cancer (BC) treatment. The aim of this study was to investigate whether women diagnosed with BC exhibit a higher incidence of cardiovascular disease (CVD).</p><p><strong>Methods and results: </strong>Matched cohort study. Using data from the Cancer Registry of Norway and the Norwegian Patient Registry, we created a nationwide cohort of women diagnosed with BC between 2013 and 2020 and age-matched controls (matching ratio 1:10). For BC patients, the index date was the date of their BC diagnosis. For controls, the index date was a random date within the index year of the matched BC patient. For eight selected CVDs, we compared the prevalence before BC diagnosis between cases and controls, as well as the overall incidence, hazard ratios (HRs), and cumulative incidences post BC diagnosis. Follow-up was through 2021. Our study population consisted of 27 526 BC patients and 269 904 matched controls. Among the subset of patients without CVD prior to index, BC patients had significantly increased overall and cumulative risk of pulmonary embolism (HR = 3.00, 95% CI: [2.51-3.59]), atrial fibrillation (1.53 [1.38-1.70]), other cardiac arrhythmias (1.43 [1.27-1.61]), heart failure (1.93 [1.33-2.80]), hypertensive heart disease (1.79 [1.67-1.91]), and heart valve disease (2.02 [1.79-2.27]).</p><p><strong>Conclusion: </strong>In this contemporary cohort, BC patients still had an increased risk of several CVDs compared to age-matched controls. Further research is needed to determine the causes of this increased risk, but clinicians should be aware and optimize therapy accordingly.</p>","PeriodicalId":93995,"journal":{"name":"European heart journal open","volume":"5 3","pages":"oeaf043"},"PeriodicalIF":0.0,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12042752/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144032407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reduced dose direct oral anticoagulants and time-in-therapeutic-range defined warfarin in new-onset atrial fibrillation: a report from the nationwide FinACAF study.","authors":"Alex Luojus, Mika Lehto, Olli Halminen, Ossi Lehtonen, Mikko Niemi, Konsta Teppo, Jaana Kuoppala, Jari Haukka, Jukka Putaala, Miika Linna, Pirjo Mustonen, Aapo Aro, Juha Hartikainen, Gregory Yoke Hong Lip, Kari Eino Juhani Airaksinen","doi":"10.1093/ehjopen/oeaf046","DOIUrl":"10.1093/ehjopen/oeaf046","url":null,"abstract":"<p><strong>Aims: </strong>Direct oral anticoagulants (DOACs) at reduced dosage regimens are the first choice of ischaemic stroke (IS) prevention for patients with atrial fibrillation (AF) and elevated bleeding risk or renal insufficiency. We compared the outcomes of reduced dose DOACs and warfarin.</p><p><strong>Methods and results: </strong>We included all new-onset patients with AF in Finland from 2011 to 2018. Adjusted hazard ratios (HRs) for IS, intracranial haemorrhage (ICH), bleeding, and mortality were calculated for dabigatran (<i>n</i> = 2 672), rivaroxaban (<i>n</i> = 1 866), apixaban (<i>n</i> = 3 936), and warfarin (<i>n</i> = 43 548). Patients on warfarin were grouped into quartiles by their individual time-in-therapeutic range (TTR), with the second best TTR quartile as a reference group for comparisons. Risk of IS was highest in the low TTR quartiles of warfarin, lowest in the best TTR quartile (0.65 95% confidence interval, 0.51-0.83), and did not differ for dabigatran, rivaroxaban, and apixaban compared with the second best TTR quartile. Risk of ICH was highest in low TTR quartiles of warfarin (HRs 7.20, 5.48-9.46 and 1.91, 1.44-2.55), and was not different in patients on dabigatran, rivaroxaban, and apixaban. Risk of all-cause death and bleeding were lowest in the two best TTR quartiles, and highest in the poorest TTR group. Mortality was higher for dabigatran, rivaroxaban, and apixaban, compared with the second best TTR quartile of warfarin.</p><p><strong>Conclusion: </strong>DOACs with reduced doses are efficient and safe stroke prevention therapy in high-risk patients with AF when compared with warfarin therapy of sufficient TTR. In this comparison, warfarin therapy of excellent TTR-quality was associated with the lowest risk of bleeding and mortality.</p>","PeriodicalId":93995,"journal":{"name":"European heart journal open","volume":"5 3","pages":"oeaf046"},"PeriodicalIF":0.0,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12066950/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144059300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An innovative cardiac rehabilitation based on the power-force-velocity profile to further improve cardiorespiratory capacities in coronary artery disease patients: CITIUS study.","authors":"Marie Fanget, Pierre Labeix, Jean-Benoit Morin, Manon Bayle, Jerome Koral, Rodolphe Testa, Nicolas Peyrot, Vincent Gremeaux, Marie-Christine Iliou, Thierry Busso, Jari Antero Laukkanen, Frederic Roche, David Hupin","doi":"10.1093/ehjopen/oeaf036","DOIUrl":"10.1093/ehjopen/oeaf036","url":null,"abstract":"<p><strong>Aims: </strong>Individually optimizing the training programme of cardiac rehabilitation (CR) remains a major concern among coronary artery disease (CAD) patients. The power-force-velocity profile (PFVP) for a given task is usually assessed to improve performance in athletes through individualized training. Therefore, assessing PFVP on stationary cycle ergometer may allow better personalization of CR programme. The aim of this study was to compare the effects of a new CR customized based on patient's PFVP vs. a traditional CR in CAD patients on cardiorespiratory, biological, and muscular systems.</p><p><strong>Methods and results: </strong>A total of 86 patients participated in this study. The 3-week intervention consisted of physical training sessions (4/week) and therapeutic education workshops (1/week). Experimental group patients followed a specific cycle ergometer training programme focusing on their less developed PFVP quality. Control patients attended a conventional CR programme. Cardiopulmonary exercise test (VO₂ at the first ventilatory threshold, VT₁, and the peak), blood tests [LDL and HDL cholesterol (LDL-C and HDL-C)], and handgrip and quadriceps force were assessed at baseline and after CR. The mean age was 60.8 ± 9.6 years, and 15% were women. A significantly greater benefit in VO₂  _peak (experimental: +21.5 ± 19.2% vs. control: +10.5 ± 15.8%, <i>P</i> < 0.001), VO₂ at VT₁ (experimental: +35.5 ± 33.6% vs. control: +8.4 ± 31.2%, <i>P</i> < 0.001), and LDL-C (<i>P</i> = 0.001) were observed in the experimental group. Both groups significantly increased HDL-C and muscle parameters.</p><p><strong>Conclusion: </strong>The novel CR, based on initial individual PFVP performed on stationary cycle ergometer, showed greater benefits on cardiorespiratory capacities and lipid profile than a conventional, non-individualized CR. Therefore, PFVP could be used in CR to adapt specifically the content of training sessions.</p>","PeriodicalId":93995,"journal":{"name":"European heart journal open","volume":"5 3","pages":"oeaf036"},"PeriodicalIF":0.0,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12152306/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144277131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endometriosis: the ongoing quest for therapeutic modulators to prevent cardiovascular adverse outcomes.","authors":"Benjamin Marchandot, Olivier Morel","doi":"10.1093/ehjopen/oeaf044","DOIUrl":"10.1093/ehjopen/oeaf044","url":null,"abstract":"","PeriodicalId":93995,"journal":{"name":"European heart journal open","volume":"5 3","pages":"oeaf044"},"PeriodicalIF":0.0,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12076400/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144082943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Practice patterns and percutaneous coronary intervention outcomes: a comparison between Sweden and the US.","authors":"Revathy Sampath-Kumar, Moman Mohammad, Sacharias von Koch, Ryan Reeves, Belal Al Khiami, Lawrence Ang, Anna Melendez, Ehtisham Mahmud, Ori Ben-Yehuda, David Erlinge","doi":"10.1093/ehjopen/oeaf045","DOIUrl":"10.1093/ehjopen/oeaf045","url":null,"abstract":"<p><strong>Aims: </strong>Comparisons of international practice patterns and their impact on percutaneous coronary intervention (PCI) outcomes are lacking. We compared temporal PCI trends between Sweden and a large university hospital system in the US.</p><p><strong>Methods and results: </strong>Data within the Swedish Coronary Angiography and Angioplasty Registry (SCAAR) and the University of California San Diego Health internal National Cardiovascular Data Registry (NCDR) CathPCI Registry were used to identify patients who underwent PCI from 2007 to 2021. Baseline characteristics and practice patterns were assessed using all patients (275 021 Swedish cohort, 9883 US cohort). Mortality was analysed using a random-effects Cox model, restricted to patients treated at university hospitals and excluding those with cardiac arrest or cardiogenic shock (108 136 Swedish cohort, 9592 US cohort). The Swedish cohort was older, had a greater proportion of men, and was more likely to smoke (all <i>P</i> < 0.001). The US cohort had a higher body mass index and was more likely to have diabetes, hyperlipidaemia, prior PCI, congestive heart failure, and peripheral arterial disease (all <i>P</i> < 0.001). Sweden had lower rates of PCI for stable angina and lower use of mechanical circulatory support (all <i>P</i> < 0.001). More STEMI patients were treated with only heparin as anticoagulation in Sweden, even in the contemporary era. There was earlier adoption and increased utilization of ticagrelor and radial access in Sweden, while there was earlier use of drug-eluting stents in the US. Fractional flow reserve was used more frequently in Sweden. There was no difference in adjusted all-cause mortality 1 year post-PCI for any indication between university hospitals in Sweden and the US (hazard ratio [HR] 1.09; 95% CI 0.86-1.37; <i>P</i> = 0.48), and this finding was consistent across subgroups.</p><p><strong>Conclusion: </strong>Despite significant differences in patient populations and practice variations, we found no difference in post-PCI mortality between university hospitals in Sweden and the US.</p>","PeriodicalId":93995,"journal":{"name":"European heart journal open","volume":"5 3","pages":"oeaf045"},"PeriodicalIF":0.0,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12053007/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144046071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival benefit of secondary prevention medical therapy in takotsubo cardiomyopathy: a Bayesian network meta-analysis.","authors":"Daud Mutahar, Ammar Zaka, Stephen Bacchi, Brandon Stretton, Joshua G Kovoor, Aashray K Gupta, Naim Mridha","doi":"10.1093/ehjopen/oeaf040","DOIUrl":"10.1093/ehjopen/oeaf040","url":null,"abstract":"<p><strong>Aims: </strong>Takotsubo cardiomyopathy (TTC) is a form of transient left ventricular systolic dysfunction without evidence of complicated coronary artery disease. Efficacy of medical therapy in secondary prevention of all-cause mortality is not well established. We performed a systematic review and network meta-analysis to compare survival benefit of secondary prevention medical therapy in patients with TTC.</p><p><strong>Methods and results: </strong>PubMed, Embase, and Cochrane were searched up to 6 January 2024. Eligible studies included multivariable-adjusted or propensity-matched studies of patients receiving medical therapy with beta-blockers, angiotensin-converting enzyme inhibitors (ACE) or angiotensin receptor blockers (ARBs), aspirin, and statins after an index presentation with TTC. The primary outcome was all-cause mortality at any time point. Secondary outcome was TTC recurrence. Random-effect hierarchical Bayesian meta-analysis was performed. We identified 13 observational studies. Takotsubo cardiomyopathy mortality was reported in 435 (4.7%) out of 9237 patients, across a median follow-up of 2.18 years. Mean age was 69.7 ± 12.5 years, and 7906 patients (90.7%) were females. Beta-blockers were associated with a statistically significant reduction in mortality compared to control [hazard ratio (HR) 0.65, 95% confidence interval (CI) (0.55-0.77)]. ACE inhibitors/ARBs showed a nonsignificant trend towards mortality reduction [HR 0.76, 95% CI (0.54-1.07)]. Statins [HR 0.96, 95% CI (0.77-1.19)] and aspirin [HR 0.87, 95% CI (0.55-1.38)] showed no significant mortality benefit. Bayesian probability ranks favoured beta-blockers as the most effective treatment for TTC mortality prevention.</p><p><strong>Conclusion: </strong>This review highlights the modest efficacy of secondary prevention medications in the management of TTC, as ACE or ARBs, beta-blockers, aspirin, and statins failed to demonstrate comparative mortality benefit. Randomized controlled trials are needed to confirm efficacy of pharmacotherapy in this vulnerable patient cohort.</p>","PeriodicalId":93995,"journal":{"name":"European heart journal open","volume":"5 3","pages":"oeaf040"},"PeriodicalIF":0.0,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12066946/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144015455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Morbidity-bridging metabolic pathways: linking early cardiovascular disease risk and depression symptoms using a multi-modal approach.","authors":"Angela Koloi, Arja Rydin, Yuri Milaneschi, Femke Lamers, Jos A Bosch, Emma Pruin, Sander W van der Laan, Pashupati P Mishra, Terho Lehtimäki, Mika Kähönen, Olli T Raitakari, Dimitrios I Fotiadis, Rick Quax","doi":"10.1093/ehjopen/oeaf038","DOIUrl":"10.1093/ehjopen/oeaf038","url":null,"abstract":"<p><strong>Aims: </strong>Prevalence of cardiovascular diseases (CVDs) and depression is rising globally. Their co-occurrence associates with poorer outcomes, potentially due to shared metabolic pathways. This study aimed to identify metabolic pathways linking depression symptoms and CVD risk factors.</p><p><strong>Methods and results: </strong>Data from the Young Finns Study (YFS, <i>n</i> = 1,599, mean age 37 ± 5, 54% female) served as input for a network (mixed graphical models). Confirmatory analysis through covariate-adjusted regression was done with UK Biobank (UKB, <i>n</i> = 69,513, mean age 63 ± 7, 64% female). Mendelian randomization assessed causality using genome-wide association studies data. The study examined 52 plasma metabolites measured by nuclear magnetic resonance spectroscopy. Outcomes included depression symptoms (BDI in YFS, PHQ-9 in UKB) and CVD risk factors [systolic/diastolic blood pressure, carotid intima-media thickness (cIMT)]. Mendelian randomization inferred causal links between metabolites and depression or (intermediate markers of) CVD. Two bridge metabolites were identified: glucose linked to sleep pattern (<i>P</i> = 0.034); omega-3 fatty acids (FAs) linked to appetite change (<i>P</i> < 0.001); and both connected to cIMT (both <i>P</i> = 0.002). Mendelian randomization suggested glucose as causal in coronary artery disease (CAD) risk, while omega-3 FAs showed potential causal links to CAD, coronary artery calcification, and cIMT.</p><p><strong>Conclusion: </strong>This study integrated three statistical techniques and identified two metabolic markers (glucose, omega-3 FAs) connecting depression and CVD on a symptom and risk factor level. The associations, established in a relatively young cohort, were replicated in a predominantly middle-aged cohort and emphasize both the generalizability of the findings across different populations and value of symptom-level analysis in depression and CVD comorbidity research.</p>","PeriodicalId":93995,"journal":{"name":"European heart journal open","volume":"5 3","pages":"oeaf038"},"PeriodicalIF":0.0,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12053008/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144059878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Energetics of flow restoration after premature ventricular contractions depends on microvascular vasodilation capacity: Insights from wave intensity analysis.","authors":"Ahmet Tas, Fevzi Alp Findik, Yaren Alan, Ilke Kara Tas, Tim P van de Hoef, Kim H Parker, Murat Sezer, Jan J Piek","doi":"10.1093/ehjopen/oeaf041","DOIUrl":"https://doi.org/10.1093/ehjopen/oeaf041","url":null,"abstract":"","PeriodicalId":93995,"journal":{"name":"European heart journal open","volume":"5 3","pages":"oeaf041"},"PeriodicalIF":0.0,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12059631/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144031794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}